Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial

• Published in: Journal of clinical oncology Vol. 41; no. 16_suppl; p. 12047
• Main Authors: Zittel, Jason, Baran, Andrea M., Dotan, Efrat, Hubbard, Joleen M., Noel, Marcus Smith, Hezel, Aram F, Tejani, Mohamedtaki Abdulaziz, Mohile, Supriya Gupta
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 01.06.2023

12047Background: Metastatic colorectal cancer (mCRC) is a leading cause of death, particularly in older adults. Regorafenib (REGO) is an FDA-approved oral multi-kinase inhibitor for refractory mCRC based on the CORRECT trial results, but older adults were underrepresented with a median age of 61 (54...